MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-03-2026
IMARA Market Cap 2011-2026 | IMRA
As of March 17, 2026 IMARA has a market cap of $ 663 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap IMARA
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 225 M | 16.3 M | 32.9 M | 224 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 225 M | 16.3 M | 124 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
962 M | $ 3.56 | 2.01 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
40.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aptorum Group Limited
APM
|
4.09 M | $ 0.79 | -0.79 % | $ 4.31 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
538 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
38.2 M | - | 10.36 % | $ 9.8 M | USA |
 |
argenx SE
ARGX
|
13.8 B | $ 703.3 | 0.41 % | $ 25 B |  Niderland |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
7.37 B | $ 231.03 | 2.23 % | $ 5 B |  Danmark |
 |
ADC Therapeutics SA
ADCT
|
1.22 B | $ 4.22 | 2.18 % | $ 105 M |  Schweiz |
 |
Alterity Therapeutics Limited
ATHE
|
895 M | $ 3.61 | 0.28 % | $ 8.69 B |  Australia |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 6.63 | -0.75 % | $ 182 M |  Israel |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
364 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
12.1 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
484 M | - | 1052.0 % | $ 415 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
71.4 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
49 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
373 M | $ 14.36 | 1.13 % | $ 210 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 90.54 | -0.71 % | $ 27.2 B | Germany |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Burford Capital Limited
BUR
|
2.09 B | $ 8.05 | 1.64 % | $ 1.31 B | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
98 M | - | - | $ 521 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
426 M | $ 6.05 | -0.82 % | $ 493 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
15.8 M | $ 2.64 | 3.94 % | $ 16.6 M | USA |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
BioCardia
BCDA
|
8.9 M | $ 1.27 | 0.79 % | $ 26.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
424 M | $ 1.51 | 4.86 % | $ 385 M | Britain |
 |
Athira Pharma
ATHA
|
16.2 M | - | - | $ 269 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.16 B | $ 3.58 | -0.56 % | $ 7.79 B | Israel |
 |
CureVac N.V.
CVAC
|
3.53 B | - | - | $ 867 M | Germany |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
Actinium Pharmaceuticals
ATNM
|
48.4 M | $ 1.11 | - | $ 33.4 M | USA |